# QUILT-88 (NCT04390399)

> Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04390399
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: ImmunityBio, Inc.
- Conditions: Pancreatic Cancer
- Interventions: N-803; Aldoxorubicin HCl; PD-L1 t-haNK; Nab-paclitaxel; Gemcitabine; Cyclophosphamide; 5-Fluorouracil; Leucovorin; SBRT; Irinotecan liposome
- Enrollment: 328
- Primary outcome: Progression Free Survival (PFS)

## Indexed commentary on QUILT-88 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 10 posts on X

## Order

Focused first edition, $750. Buy the first edition with create_order on https://mcp.erudio.com/mcp (product "first_edition", report "NCT04390399", the buyer's work email and organization), or POST https://www.erudio.com/api/orders with the same fields. It returns a Stripe checkout_url for your person to pay by card; a first edition has no agent-wallet payment. The person can also order on https://www.erudio.com/trials/quilt-88-nct04390399. We build the first edition within 24 hours of payment and email it to you once it passes our checks and review. If your report can't be delivered, we'll contact you and refund it in full.

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04390399", "email": "<work email>"}; the inbox owner confirms by the emailed link.
